# US 2019/0167819 A1 · Contrast agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167819 A1
- Document ID: US20190167819A1
- Status: Published application
- Kind: A1
- Application number: 16/092,905
- Filed: 2017-04-05
- Published: 2019-06-06
- Earliest claimed: 2016-04-13
- Assignees: Bracco Imaging S.P.A.
- Applicants: Bracco Imaging S.P.A.
- Inventors: Luciano LATTUADA; Roberta NAPOLITANO; Valeria BOI; Massimo VISIGALLI; Silvio AIME; Giovanni Battista GIOVENZANA; Alberto FRINGUELLO MINGO
- Web page: https://patentgrep.com/patent/US20190167819A1

## CPC

- A61K 49/106: {the complex-forming compound being cyclic, e.g. DOTA}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 257/02: not condensed with other rings
- C07F 9/6524: having four or more nitrogen atoms as the only ring hetero atoms
- G01R 33/5601: {involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- G01R: MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES (indicating correct tuning of resonant circuits H03J3/12)

## Abstract

The present invention relates to new class of functionalized polyazamacrocycles including at least one phosphonic or phosphinic group linked to a nitrogen atom of the macrocyclic cage, and capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.

## Claims

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A compound according to claim 1 in which L in the formula (I) is a direct bond, and Z is a substituted phenyl, or a C1-C6 alkyl chain that is optionally interrupted by one or more groups selected from —O—, —NH— and —CO—, and is substituted by one or more groups selected from hydroxyl, carboxyl, halogen atoms, or by a group of formula —O—(CH2)m—Ar, —NHSO2R5, —NHC(O)NHR6, —NHC(O)OR7 or —NR8R9.

### Claim 4 (depends on 3)

A compound according to claim 3 in which Z is a substituted phenyl, having the formula (III)
in which Q is a substituent group selected from the group consisting of: hydroxyl, —NH2, C1-C3 alkoxy, C1-C3 hydroxyalkyl, and carboxyl.

### Claim 5

(canceled)

### Claim 6 (depends on 3)

A compound according to claim 3 in which Z is a C1-C6 alkyl chain that is interrupted by one or more oxygen —O— atom(s) and/or substituted by a group of formula —O—(CH2)mAr having the formula (IV)
in which p is 0 or 1; Ar is a phenyl ring, which can be either unsubstituted or substituted by a group selected from the group consisting of: hydroxyl, C1-C3 alkoxy and carboxyl of formula —(OCH2)mCOOH or —(CH2)mCOOH where m is 0 or 1.

### Claim 7

(canceled)

### Claim 8 (depends on 3)

A conipound according to claim 3 in which Z is a C1-C6 alkyl comprising a substituent group selected from the groups of formula —NHSO2R5, —NHC(O)NHR6,—NHC(O)OR7 and —NR8R9.

### Claim 9 (depends on 1, 8)

A compound according to claim 8 having the formula (V)
in which R5 is an optionally perfluorinated C1-C3 alkyl; or an aryl or cycloalkyl ring;
or the formula (VI)
in which R6 is a C1 -C3 alkyl optionally substituted by a phenyl or a cyclohexyl ring, or is an aryl or cycloalkyl ring;
or the formula (VII)
in which R7 is a C1-C 5 alkyl optionally interrupted by one or more oxygen atom(s) and optionally substituted by a phenyl or a cyelohexyl ring, or is an aryl or cycloalkyl ring;
or the formula (VIII)
in which:
R8 is an aryl or cycloalkyl ring; or a C1-C5 alkyl optionally comprising one or more substituent groups selected from hydroxyl, C1-C3 alkoxy, C1-C3 hydroxyalkoxy, an optionally substituted phenyl or cyclohexyl ring, and a macrocyclic residue T;
R9 is a hydrogen atom, or a group selected from the groups of formula —(CH2)nPO(OR′)2, —(CH2)nPO(R4)(OR′) and —(CH2)nCOOR′ in which n, R′ and R4 are as defined in claim 1.

### Claim 10 (depends on 1)

A compound according to claim 1 in which in the formula (I) Z is a macrocyclic residue of formula —W—G—W′—T, having the formula (IX)
in which:
L is an alkylene chain —(CH2)n— where n is an integer from 1 to 3; W and W′ represent, the same or different from each other, a divalent group selected from —O—, —SO2NH—, —NHSO2—, —CONH— and —NHCO—; G is a bifunctional residue selected from a phenylene (—C6H4—) and a C1-C5 linear or branched alkylene optionally interrupted by one or more oxygen atoms, and optionally substituted by one or more groups selected from hydroxyl, phenyl and carboxyl.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A compound according to claim 1 in which in the formula (I) one of Y1, Y2 and Y3 is a carboxyl of formula —COOR′ and the other two, independently from one another, are selected from —PO(OR′)2 and —PO(R4)(OR′).

### Claim 13 (depends on 1)

A compound according to claim 1 in which in the formula (I) one of Y1, Y2 and Y3 is selected from —PO(OR′)2 and —PO(R4)(OR′) and the remaining two are carboxyls of formula —COOR′.

### Claim 14 (depends on 1)

A compound according to claim 1 in which in the formula (I) R′ is H.

### Claim 15 (depends on 1)

A compound of formula (I) according to claim 1 selected from the group consisting of:
and the physiologically acceptable salt thereof.

### Claim 16 (depends on 1)

A compound of formula (I) according to claim 1, in the form of a complex with a paramagnetic metal ion selected from the group consisting of Fe(2+), Fe(3+), Cu(2+), Cr(3+), Gd(3+), Eu(3+), Dy(3+). La(3+), Yb(3+) and Mn(2+), or of a physiologically acceptable salt thereof.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A compound of formula (I) according to claim 1, wherein the physiologically acceptable salt is with a cation of an inorganic base selected from an alkali or alkaline-earth metal selected from potassium, sodium, calcium or magnesium, or of an organic base selected from ethanolamine, diethanolamine, morpholine, glucamine, N-methylglucamine, N,N-dimethylglucamine or of an amino acid selected from lysine, arginine and omithine or, optionally, with an anions of inorganic acids selected from halo acids as well as of other suitable ions selected from acetate, succinate, citrate, fumarate, maleate or oxalate.

### Claim 19

(canceled)

### Claim 20 (depends on 16)

A pharmaceutical composition comprising a compound of formula (I) in the form of paramagnetic metal complex, or of a pharmaceutical salt thereof, as defined in claim 16 in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

### Claim 21 (depends on 1)

A process for the preparation of the compounds of formula (I) as defined in claim 1 comprising the following main steps:
a) Obtaining a macrocyclic substrate 1 in a suitable protected form, e.g. in which the carboxylic groups of the substrate are protected as tert-butyl esters;
b) Obtaining an alkylating molecule 2, in which any optional functional group(s) not involved with the coupling reaction with the substrate 1 is suitably protected;
c) Coupling the protected substrate 1 with the alkylating molecule 2, to give the desired compound of formula (I) in a suitably protected form or, alternatively, an intermediate thereof 3;
d) Optionally converting the intermediate obtained at the step c) of the process in the suitably protected compound of formula (I);
e) Removing any protecting group and isolating the cheating ligand of formula (I); and
f) Complexing the obtained ligand with a suitable paramagnetic metal ion and isolating the chelate complex, or the salt thereof.

### Claim 22 (depends on 20)

A method for the in vivo imaging a human or animal body organ or tissue by use of the MRI technique that comprises the steps of:
a) submitting a human or animal pre-administered with a composition composition according to claim 20 comprising a compound of formula (I) in the form at paramagnetic metal complex, or of a pharmaceutically acceptable salt thereof, and positioned in a MRI imaging system, to a radiation frequency selected to excite the non-zero proton spin nuclei of the active paramagnetic substrate; and
b) recording a MR signal from said excited nuclei.

### Claim 23 (depends on 16)

A method for the in vitro (ex vivo) imaging of biological samples, including cells, biological fluids and biological tissues originating from a patient, by use of the MRI technique, that comprises contacting an effective amount of a paramagnetic complex compound at formula (I) or of a physiologically acceptable salt thereof as defined in claim 16 with the biological sample of interest and then obtaining MRI signals from said samples by use of the MRI technique.

### Claim 24

(canceled)

### Claim 25 (depends on 9)

A compound according to claim 9 in which in the formula (VIII) R8 is a macrocyclic residue T.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

A compound according to claim 1 in which in the formula (I) R1, R2 and R3 are H.

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 10)

A compound according to claim 10 in which in the formula (IX) Y1 is the same as Y1′, Y2 is the same as Y2′, and Y3 is the same as Y3′.
